21 results about "Ambroxol" patented technology

The application provides an ambroxol oral dissolving film composition, a preparation method and application thereof. The ambroxol oral dissolving film composition comprises an active drug, a film forming material and a taste masking agent, and the active drug is 2-amino-3,5-dibromo-N-(trans-4-hydroxycyclohexyl) benzylamine and / or a pharmaceutically acceptable salt thereof, for example, ambroxol hydrochloride. The ambroxol oral dissolving film composition provided by the application has the advantages of thin thickness, good taste, stable properties, immediate dissolution in the oral cavity without drinking water, and fast oral absorption speed. Moreover, the ambroxol oral dissolving film composition has the advantages of simple process, high drug loading, good drug content uniformity, and good market prospect.

The invention discloses a production process of an ambroxol oral solution, and belongs to the technical field of chemical medicinal preparations, the production process comprises the following steps: adding an aqueous solution containing ambroxol hydrochloride, clenbuterol hydrochloride, sorbitol, propylene glycol, glycerol, hydroxyethyl cellulose, DL-tartaric acid and sodium benzoate into a reaction kettle, and uniformly stirring to obtain the ambroxol hydrochloride oral solution, the clenbuterol hydrochloride, the sorbitol, the propylene glycol, the glycerol, the hydroxyethyl cellulose, the DL-tartaric acid and the sodium benzoate; the preparation method comprises the following steps: preparing in a production system passivated by hydroxyethyl diamine tetraacetic acid trisodium salt, treating by a two-stage series hollow membrane contactor, and finally filling a glass bottle with a liquid medicine. According to the preparation method disclosed by the invention, on the basis of prescription adjustment without adding antioxidants such as sodium pyrosulfite and the like, the impurities of the medicine in the production and storage processes are obviously reduced, the product stability and the clinical medication safety are improved, and the preparation process is simple and stable to operate and suitable for industrial production.

The invention relates to solid compositions and methods of manufacture. The present invention addresses the problem of providing a solid composition which contains at least one component selected from the group consisting of loxoprofen, salts thereof, and hydrates thereof, and another component, and in which changes in properties are suppressed. [Solution] A solid composition containing the following components: (A) at least one substance selected from the group consisting of loxoprofen, salts thereof, and hydrates thereof; (B) fructose; and (C) one or more components selected from the group consisting of: (C-1) vitamin B1 and vitamin C; (C-2) Chinese herbaceous peony, liquorice and valerian; (C-3) bromhexine, ambroxol, tepiperidine, salts thereof, and hydrates thereof; (C-4) clomastine, salts thereof, and hydrates thereof; and (C-5) dextromethorphan, salts thereof, and hydrates thereof.

The present application relates to the technical field of nucleic acid extraction and purification, and particularly relates to a DNA and RNA co-extraction reaction reagent and an extraction method, the reaction reagent comprising a nucleic acid protective agent RP, a sample lysis and binding liquid LB, a protein washing liquid WB1, a nucleic acid rinsing liquid WB2, and a nucleic acid elution liquid EB; the nucleic acid protective agent RP comprising DTT, mercaptoethanol, TCEP, and sodium hydroxide; the sample lysis and binding liquid LB comprising Tris-HCl, benzenesulfonic acid, sodium citrate, guanidine hydrochloride, guanidine isothiocyanate, guanidine thiocyanate, urea, triton X-100, SDS, potassium chloride, sodium chloride, bromhexine, N-acetylcysteine, ambroxol hydrochloride, isopropyl alcohol, and anhydrous ethanol; the protein washing liquid WB1 comprising Tris-HCl, benzenesulfonic acid, sodium citrate, guanidine hydrochloride, guanidine isothiocyanate, guanidine thiocyanate, urea, triton X-100, sodium chloride, isopropyl alcohol, and anhydrous ethanol; the nucleic acid rinsing liquid WB2 comprising Tris-HCl, sodium chloride, isopropyl alcohol, and anhydrous ethanol; and the nucleic acid elution liquid EB being nuclease-free water; the reagent can rapidly and fully enrich and purify DNA and RNA of a sample simultaneously.

The invention provides a method for detecting clenbuterol hydrochloride by removing hydroxyethyl cellulose in an ambroxol oral solution. According to the present invention, the high performance liquid chromatography is adopted, the HEC can form the precipitate capable of being centrifugally separated by using the acetonitrile-isopropanol mixed solvent, the interference source of the HEC is directly completely removed through the simple liquid-solid separation, the content of the clenbuterol hydrochloride is not affected, the viscosity of the test solution is equivalent to the viscosity of the mobile phase, and the detection result is accurate. According to the method, the chromatographic column is fundamentally prevented from being blocked and polluted, the service life of the chromatographic column is prolonged, a protection column is not needed, the cost is saved, the viscosity of a sample is reduced, the peak area of the clenbuterol hydrochloride is large, and the repeatability is obviously improved. The method is high in specificity, high in linearity, accuracy and precision and good in durability.

In certain embodiments, liquid formulations for oral administration are disclosed, comprising an amphiphilic material and ambroxol or a pharmaceutically acceptable salt thereof.

The invention provides a polypeptide coupling medicine and application thereof. The polypeptide coupling medicine comprises antiviral polypeptide, connecting polypeptide, amino acid and ambroxol which are connected in sequence. The polypeptide coupling drug provided by the invention is obtained by coupling a coronavirus membrane fusion inhibitor and ambroxol, and is formed by coupling polypeptide serving as a targeting carrier and a load drug through a connexon via a covalent bond. Through polypeptide coupled drug activity evaluation and pharmacokinetic research, evaluation of activity changes of polypeptide and ambroxol and research on drug exposure and half-life periods of inhalants and injections, the polypeptide coupled drug retains antiviral activity of polypeptide and phlegm eliminating / respiratory tract regulating functions of ambroxol, the drug exposure is increased, and the half-life period is prolonged.

The application provides an ambroxol oral dissolving film composition, a preparation method and application thereof. The ambroxol oral dissolving film composition comprises an active drug, a film forming material and a taste masking agent, and the active drug is 2-amino-3,5-dibromo-N-(trans-4-hydroxycyclohexyl) benzylamine and / or a pharmaceutically acceptable salt thereof, for example, ambroxol hydrochloride. The ambroxol oral dissolving film composition provided by the application has the advantages of thin thickness, good taste, stable properties, immediate dissolution in the oral cavity without drinking water, and fast oral absorption speed. Moreover, the ambroxol oral dissolving film composition has the advantages of simple process, high drug loading, good drug content uniformity, and good market prospect.

The present application provides a kind of antitussive and expectorant medicine, by adding flurbiprofen to traditional strong loquat, in addition to the anti-inflammatory effect of flurbiprofen, it can also significantly improve the antitussive and expectorant efficacy of traditional strong loquat; Patients do not need to take other expectorant drugs at the same time, such as ambroxol, etc., improve the compliance of cough and phlegm patients for drugs, and show obvious advantages in clinic.

The utility model discloses an ambroxol hydrochloride oral solution filtering and stirring device which comprises a stirring box, the inner wall of the stirring box is rotationally connected with a driving rod through a sealing bearing, stirring blades are installed below the outer wall of the driving rod, a feeding port is formed in the top of the stirring box, a discharging valve is installed at the bottom of the stirring box, and a discharging port is formed in the bottom of the stirring box. And a cleaning structure is arranged above the stirring blades and comprises a screen. The utility model relates to the technical field of solution production equipment, through the cooperation of a screen, a fixing plate and a supporting plate, the screen is placed between the supporting plate and a pressing plate, after the screen is installed, a driving rod is used for driving a strip box to rotate, the screen can rotate around the driving rod, and under the driving of a transmission structure, the screen can rotate, so that the production efficiency is improved. Sediments in the oral liquid are filtered in advance, and the situation that excessive sediments are accumulated on the filter screen at the bottom in the subsequent filtering process, and the filtering effect is affected is avoided.

A method for purifying a crude flavor or perfumery or cosmetic ingredient or intermediate, for example crude (−)-Ambrox, comprising a number of washing steps, the products of said method, and uses of said product.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an ambroxol hydrochloride oral solution and a preparation process thereof, and the preparation process comprises the following steps: heating purified water to 60-80 DEG C, adding sorbitol and L-cysteine into the purified water, stirring and dissolving for 10-30 minutes, adding hydroxyethyl cellulose, uniformly dispersing, and cooling to 48-52 DEG C to obtain a first mixed solution; adding ambroxol hydrochloride, benzoic acid and glycerol into the first mixed solution, stirring until the ambroxol hydrochloride, benzoic acid and glycerol are completely dissolved, finally adding essence, and uniformly mixing; and finally, fixing the volume to a set volume by adopting purified water. According to the preparation method disclosed by the invention, through collaborative optimization of dual effects of L-cysteine and a specific feeding sequence, even if the content of sorbitol reducing sugar is greater than 0.3%, the content of an impurity B can still be controlled to be less than or equal to 0.3%, the content of an impurity F can still be controlled to be less than or equal to 0.2%, the deviation between the content of related substances and a reference preparation is less than or equal to + / -0.3%, and the stability is excellent.

This invention discloses a human olfactory receptor-derived peptide and a biosensor for monitoring ambroxol, belonging to the field of biosensors. Existing methods for detecting ambroxol are cumbersome and costly, and traditional sensing materials have poor selectivity. The amino acid sequence of the derived peptide of this invention is shown in SEQ ID NO: 2. The biosensor includes an Al₂O₃ substrate, 14 pairs of gold interdigitated electrodes, and the electrodes are modified with a single-walled carbon nanotube conductive layer, with the carbon nanotubes covalently linked to the derived peptide. This sensor specifically recognizes ambroxol, shows no significant response to 12 interfering substances, has a detection limit of 50 ppb, an effective detection range of 50 ppb to 5 ppm, and exhibits good stability and adaptability to temperature and humidity. This invention has great practical application potential in the quality control of the ambroxol-related industry.

This invention proposes a compound ambroxol sustained-release microsphere and its preparation method. The compound ambroxol sustained-release microsphere comprises ambroxol hydrochloride, clenbuterol hydrochloride, and a cellulose ester sustained-release material, effectively controlling the dissolution differences between ambroxol hydrochloride and clenbuterol hydrochloride, enabling simultaneous and stable release of both drugs and avoiding efficacy fluctuations due to different release rates. Furthermore, the microsphere utilizes a hot-melt extrusion process, ensuring uniform dispersion of the two active pharmaceutical ingredients within the sustained-release material, thus resolving the uniformity issue caused by low clenbuterol hydrochloride content. The preparation process requires no organic solvents, eliminating solvent residues and preventing degradation or reactions of the active pharmaceutical ingredients in solvents, thereby improving product stability.

This invention belongs to the field of organic synthesis technology and provides a method for preparing a key intermediate of ambroxol hydrochloride. The method includes the following steps: methyl 2-aminobenzoate reacts with a brominating reagent under the action of an initiator to generate methyl 2-amino-3,5-dibromobenzoate via a bromination reaction; subsequently, methyl 2-amino-3,5-dibromobenzoate is reduced to 2-amino-3,5-dibromobenzyl alcohol in a reduction system; finally, under the action of an oxidizing agent, 2-amino-3,5-dibromobenzyl alcohol is further oxidized to form the target compound 2-amino-3,5-dibromobenzaldehyde. The optimized process has mild reaction conditions, conforms to green and environmentally friendly principles, significantly improves route safety, uses inexpensive and readily available raw materials, and achieves high product yield and purity, making it suitable for industrial production.

The present invention provides an ambroxol oral dissolving film composition, a preparation method therefor, and use thereof. The ambroxol oral dissolving film composition comprises an active drug, a film-forming material, and a taste masking agent. The active drug is 2-amino-3,5-dibromo-N-(trans-4-hydroxycyclohexyl)benzylamine and / or a pharmaceutically acceptable salt thereof, such as ambroxol hydrochloride. The ambroxol oral dissolving film composition provided by the present invention has the advantages of small thickness, good taste, stable properties, immediate dissolution in the mouth without drinking water, and high oral absorption speed. Moreover, the ambroxol oral dissolving film composition has a simple process, high drug-loading capacity, good drug content uniformity, and good marketization prospects.

This utility model relates to the field of ambroxol preparation technology, specifically an ambroxol preparation device, including a tank, a rotating tube, an L-shaped tube, a first sleeve, a first spring, and a first scraper. The rotating tube is rotatably connected to the top of the tank, and the L-shaped tube is fixedly connected to one end of the bottom of the rotating tube and communicates with the rotating tube. The bottom of the L-shaped tube is provided with a first through hole. The first sleeve is slidably connected to the bottom of the outer wall of the L-shaped tube and is provided with multiple first water spray holes at the bottom of the first sleeve. The first spring is fixedly connected to the bottom of the first sleeve, and one end of the first spring extends through the first through hole into the interior of the L-shaped tube and is fixedly connected to the L-shaped tube. The first scraper is fixedly connected to the bottom of the first sleeve. Through the design of the rotating tube, L-shaped tube, first sleeve, first scraper, support tube, second sleeve, and second scraper, this utility model can not only stir the raw materials in the tank, but also clean the inside of the tank.

The invention relates to analog forms of ambroxol and related compounds, compositions comprising same, and methods of preventing and / or treating various diseases and medical conditions involving the administration of analogs of ambroxol and related compounds.

1. The name of the design product: packaging box (ambroxol hydrochloride oral solution). 2. The use of the design product: for product outer packaging. 3. The design points of the design product: in the combination of shape and pattern. 4. The picture or photo that best indicates the design points: unfolded state reference drawing.

The invention provides application of combination of ambroxol and ferulic acid in preparation of a preparation for preventing and / or treating radiation-induced lung injury, and belongs to the technical field of biological medicine. The ambroxol and the ferulic acid are combined for use, so that a good prevention and treatment effect on radiation-induced lung injury caused by ionizing radiation can be achieved, early-stage acute radiation pneumonitis can be inhibited, a long-term lung function can be improved, and lung fibrosis can be blocked. On the premise of remarkably reducing the administration dosage of ambroxol and ferulic acid, the survival rate of a radiation-induced lung injury model mouse is increased by 55%, expression of TNF-alpha and TGF-beta1 is more effectively inhibited, no toxic or side effect is generated on normal alveolar epithelial cells, and the pharmaceutical composition is suitable for clinical application. The traditional Chinese medicine composition has the advantages of small dosage, excellent prevention and / or treatment effect, no toxic or side effect, no dose dependence and the like.

To provide a solid composition containing at least one selected from the group consisting of loxoprofen, a salt thereof and a hydrate thereof, and other components, and having suppressed property change.SOLUTION: (A) at least one member selected from the group consisting of loxoprofen and salts and hydrates thereof, (B) fructose, and (C) one or more members selected from the group consisting of (C- 1) vitamin B1 and vitamin C, (C- 2) peony root, licorice, and valerian, (C- 3) bromhexine, ambroxol, tipepidine and salts and hydrates thereof, (C- 4) clemastine and salts and hydrates thereof, and (C- 5) dextromethorphan and salts and hydrates thereof; A solid composition comprising: SELECTED DRAWING: None